Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.

Trisha Michel Wise-Draper Shuchi GulatiSarah PalackdharryBenjamin H HinrichsFrancis P WordenMatthew O OldNeal E DunlapJohn M KaczmarYash PatilMuhammed Kashif RiazAlice TangJonathan MarkChad ZenderAnn M GillenwaterDiana BellNicky KurtzweilMaria MathewsCasey L AllenMichelle L MierzwaKeith CasperRoman JandarovMario Medvedovic Jiun-Kae Jack LeeNusrat HarunVinita TakiarMaura L Gillison

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Neoadjuvant and adjuvant pembrolizumab increased one-year DFS rate in intermediate-risk, but not high-risk, HNSCC relative to historical control. PR to neoadjuvant ICB is a promising surrogate for DFS.

Keyphrases

phase ii
locally advanced
clinical trial
rectal cancer
open label
lymph node
early stage
squamous cell carcinoma
radiation therapy
advanced non small cell lung cancer
double blind
phase iii
study protocol
placebo controlled
randomized controlled trial